US Senate Committee Approves FDA Commissioner NomineeBy
The US Senate Committee on Health, Education, Labor & Pensions (HELP) has approved the nomination of Dr. Stephen Hahn of MD Anderson Cancer Center to serve as the next Commissioner of the US Food and Drug Administration (FDA). The vote for his confirmation now goes to the full Senate.
Dr. Hahn is the Chief Medical Executive at the University of Texas MD Anderson Cancer Center in Houston, Texas and Professor, Department of Radiation Oncology, Division of Radiation Oncology at MD Anderson. He was nominated by President Donald Trump after FDA Acting Commissioner Dr. Norman Sharpless, who served from April 5, 2019 to November 1, 2019, completed his tenure. Dr. Sharpless had replaced Scott Gottlieb, who stepped down as FDA Commissioner earlier this year (April 2019).
The Senate HELP Committee approved his nomination by a bipartisan vote of 18 to 5 in favor of his nomination. Additionally, the committee said that it had received 13 letters of support for Dr. Hahn, representing nearly 80 organizations on representing doctors, patients, researchers and colleagues. Five previous FDA Commissioners also supported Dr. Hahn.